[Skip to Content]
[Skip to Content Landing]
Views 213
Citations 0
Medical News and Perspectives
February 8, 2012

NIH Program Helps Developers Navigate Path to New Drugs for Neglected Diseases

JAMA. 2012;307(6):549-550. doi:10.1001/jama.2012.83

Competition to cross the so-called Valley of Death has become rather stiff at the National Institutes of Health (NIH).

Since 2009, the NIH's Therapeutics for Rare and Neglected Diseases (TRND) program has solicited proposals from scientists and pharmaceutical companies trying to navigate that dead zone between discovering promising compounds and getting them into human clinical trials. To date, TRND has received 125 applications for nonmonetary assistance; 10 have gotten the green light.

First Page Preview View Large
First page PDF preview
First page PDF preview